Arrowstreet Capital Limited Partnership Sells 8,317,781 Shares of Bristol Myers Squibb Company $BMY

Arrowstreet Capital Limited Partnership decreased its position in Bristol Myers Squibb Company (NYSE:BMY) by 48.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,872,779 shares of the biopharmaceutical company’s stock after selling 8,317,781 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Bristol Myers Squibb were worth $538,134,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in BMY. Swiss RE Ltd. acquired a new position in shares of Bristol Myers Squibb in the fourth quarter valued at about $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the 2nd quarter worth about $25,000. Physician Wealth Advisors Inc. raised its stake in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares in the last quarter. Bayban bought a new stake in Bristol Myers Squibb in the 4th quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth approximately $32,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on BMY. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Bank of America dropped their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Cantor Fitzgerald reiterated a “neutral” rating and set a $54.00 target price on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $61.25.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $61.56 on Friday. The firm’s 50 day simple moving average is $57.39 and its 200 day simple moving average is $58.00. The firm has a market capitalization of $125.71 billion, a price-to-earnings ratio of 17.29, a P/E/G ratio of 0.17 and a beta of 0.23. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter last year, the business posted $1.80 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY was highlighted as rising while the broader market dipped, suggesting investors were rotating into the name and viewing it as relatively resilient versus the market. Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
• Positive Sentiment: Wall Street expectations point to earnings growth in next week’s report, and multiple articles framed Bristol Myers Squibb as having a strong chance to beat estimates, which can support the stock into the print. Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
• Positive Sentiment: An analyst-style momentum piece also described BMY as a top long-term momentum stock, reinforcing a constructive technical/relative-strength narrative. Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: Bristol Myers Squibb is scheduled to report quarterly earnings next week, keeping the stock in a wait-and-see mode as investors look for confirmation of growth and guidance. Bristol Myers Squibb (BMY) to Release Quarterly Earnings on Thursday
• Neutral Sentiment: News that Alexandria Real Estate delivered a new Bristol Myers Squibb R&D hub in San Diego is operationally positive, but it is more of a long-term business development update than an immediate stock catalyst. Alexandria Real Estate Equities Delivers 427,000 RSF Bristol Myers Squibb R & D Hub
• Negative Sentiment: One MarketWatch item noted BMY underperformed peers despite daily gains, which suggests the move may be less impressive on a relative basis than it first appears. Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.